NCT06459921View on ClinicalTrials.gov

Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

December 31, 2028

Conditions

Neoadjuvant ChemotherapySintilimabLocally Advanced Gastric Cancer

Interventions

DRUG

SOX+Sintilimab

Patients would be allocated to the SOX+Sintilimab group.

DRUG

FLOT+Sintilimab

Patients would be allocated to the FLOT+Sintilimab group.

All Listed Sponsors

lead

Xijing Hospital

OTHER

NCT06459921 - Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter